

## PROVINCIAL FUNDING SUMMARY

### Pazopanib hydrochloride (Votrient) for Metastatic Renal Cell Carcinoma (pCODR 10000)

pERC Recommendation: Recommend

For further details, please see [pERC Final Recommendation](#)

Notification to Implement Issued by pCODR: January 20, 2012

This information is current as of May 1, 2020.

NOTE: Funding criteria as listed on the decision date. Please refer to the provincial drug programs for the most recent funding criteria and program eligibility.

PROVINCE	STATUS	DECISION DATE	FUNDING CRITERIA
BC	Funded	Sep 1, 2011	Advanced renal cell carcinoma; no prior systemic therapy (first-line therapy) or prior cytokines; ECOG performance status 0-2; and Compassionate Access Program (CAP) approval granted by BCCA
AB	Funded	Feb 29, 2012	Criteria Updated: As an option in the first-line treatment of advanced or metastatic clear cell renal cell carcinoma for patients with good performance status or if patients are unable to tolerate ongoing sunitinib. Not to be used after progression on sunitinib. Second-line option following ipilimumab/nivolumab in intermediate or poor risk advanced renal cell carcinoma.
SK	Funded	Mar 1, 2012	Treatment of advanced or metastatic clear cell renal carcinoma (mRCC) in patients who are unable to tolerate ongoing use of an effective dose of sunitinib. REVISED Criteria Sept 13, 2013: First-line treatment for advanced metastatic renal cell carcinoma in patients with good performance status (ECOG 0 -2), or as treatment of advanced or metastatic clear cell renal carcinoma (mRCC) in patients who are unable to tolerate ongoing use of an effective dose of sunitinib when used as a first-line treatment.
MB	Funded	Jul 17, 2013	For patients with advanced or metastatic clear cell renal carcinoma who, based on the mutual assessment of the treating physician and patient, are unable to tolerate ongoing use of an effective dose of Sunitinib

PROVINCE	STATUS	DECISION DATE	FUNDING CRITERIA
ON	Funded	Nov 7, 2012	<p>For the treatment of advanced or metastatic renal cell carcinoma of clear cell histology in patients meeting the following criteria:</p> <ul style="list-style-type: none"> <li>i) are unable to tolerate ongoing use of an effective dose of sunitinib, as mutually assessed by the requesting physician and the patient; AND</li> <li>ii) have a MSK1 prognostic score of favourable risk or intermediate risk; AND</li> <li>iii) have an ECOG2 performance status of 0-1</li> </ul> <p>1MSK = Memorial Sloan-Kettering 2ECOG = Eastern Cooperative Oncology Group Performance Status</p> <p>Renewals are considered for patients who:</p> <ul style="list-style-type: none"> <li>i) have benefited from therapy (i.e. no disease progression) and is expected to continue to do so; AND</li> <li>ii) have a performance status of ECOG 0-1</li> </ul> <p>Exclusion Criteria: Funding for Votrient will not be approved for patients who demonstrate disease progression while on sunitinib, sorafenib, temsirolimus, or everolimus.</p>
NS	Funded	Jul 3, 2012	<p>As an alternate single agent first line treatment for patients with documented evidence of histologically confirmed advanced or metastatic clear cell renal cell carcinoma who have an ECOG performance status of 0 or 1 and are unable to tolerate sunitinib</p>
NB	Funded	Jul 31, 2012	<p>For the treatment of advanced or metastatic renal cell (clear cell) carcinoma (mRCC) in patients who are unable to tolerate sunitinib and who have an ECOG performance status of 0 or 1</p>
NL	Funded	Feb 6, 2012	<p>For patients with advanced or metastatic clear cell renal carcinoma who, based on the mutual assessment of the treating physician and the patient, are unable to tolerate ongoing use of an effective dose of sunitinib.</p> <p>Renewal criteria: Written confirmation from the clinical physician that the patient has benefited from therapy and is expected to continue to do so.</p>
PEI	Funded	Jan 21, 2013	<p>For the treatment of advanced or metastatic renal cell (clear cell) carcinoma (mRCC) in patients who are unable to tolerate sunitinib and who have an ECOG performance status of 0 or 1</p>